Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
Tocilizumab
•
GCA
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
Related Questions
How would you approach management of nodular scleritis in the setting of suspected GCA?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
Do you utilize temporal artery ultrasound in your practice?
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
How do you approach the management of patients with moderate to high pre-test probabilty of GCA who are found to have negative findings on temporal artery biopsy?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How do you approach the management of aortitis in patients with ANCA-associated vasculitis?
